Add this topic to your myFT Digest for news straight to your inbox
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Continent’s drugmakers need to pay up to attract and retain talent, says Pascal Soriot
Swiss pharma group has jettisoned 16 drugs that ‘don’t have the promise to be transformative medicines’
Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria
UK research highlights risk of over-diagnosis and gaps in spotting serious variants of the disease
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Europe’s regulations have become ‘too burdensome’ and could hinder innovation, argues Michael Lohan
Novo Nordisk and Eli Lilly, plus a clutch of rivals, aim to cut side effects while treating obesity-linked diseases
UK pharma group’s chief has a fresh challenge — persuading investors that its best days are not behind it
Danish group seeks to branch out from diabetes and weight loss drugs with Cardior acquisition
Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs
Acquisition gives pharmaceutical group mid-stage asset to challenge Novartis in new form of cancer care
Booming sector raises tough questions for ESG investors
Breakthrough medicine will now be subject to further review by committee of independent experts
Drugmaker releases promising trial results for a pill and expects to enter China this year
Nice fails to approve Enhertu due to value-for-money concerns despite it being recommended in Scotland
US group hunts for outsourcers to lift production of Zepbound as it takes on Danish group’s Wegovy blockbuster
New Pasteur Institute head highlights risks posed by shortages of money, staff and political goodwill
GHO Capital has put contract research group FairJourney Biologics up for sale
Replacing a top researcher with a private sector manager would send entirely the wrong signal
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years
Leaving the EU was supposed to liberate Britain’s cumbersome approvals system and unlock new industries. What is going wrong?
German pharma group finds no unexpected side effects during trial, including at higher doses
Head of Cancer Research UK calls for more investment and points to heavy reliance on philanthropic funding
Best-selling Tagrisso drug slows progression of most common form of the disease at an early stage
International Edition